Skip to main content
Premium Trial:

Request an Annual Quote

John West, John Stuelpnagel, Tristan Orpin, Christian Henry, Matt Posard, Omead Ostadan, Blaine Bowman, Roy Whitfield, Joe Keegan, Timothy Harkness, Thomas O’Lenic, Robert Murray, Steven Owings, Gene Myers, David Deems

Illumina has made several management changes in the wake of its acquisition of Solexa last week (see related article, this issue). John West, the former CEO of Solexa, has joined Illumina as senior vice president and general manager of the sequencing business. John Stuelpnagel, Illumina’s COO, will now also serve as general manager of the company’s microarray business. Tristan Orpin, Illumina’s vice president of sales, has been promoted to senior vice president in charge of all commercial operations. Christian Henry, vice president and CFO, has been promoted to senior vice president and CFO and has assumed the additional responsibility of investor relations. Matt Posard, vice president of marketing, is now vice president of sales, while Omead Ostadan, formerly vice president of marketing at Solexa, will replace Posard as vice president of marketing at Illumina. In addition, Blaine Bowman and Roy Whitfield have joined Illumina’s board of directors from Solexa’s board of directors. 

Molecular Devices’ board of directors has awarded cash bonuses to its top executives under a bonus award program for fiscal 2006. According to a US Securities and Exchange Commission filing, President and CEO Joe Keegan will receive a bonus of $468,154; CFO Timothy Harkness will receive $282,012; Thomas O’Lenic, vice president of North American sales and service, will receive $129,264; Patricia Sharp, vice president of human resources, will receive $139,447; and Robert Murray, vice president of worldwide operations, will receive $109,926.

Sequenom has named Steven Owings vice president of commercial development, prenatal diagnostics. Owings will lead commercialization of Sequenom’s non-invavsive prenatal diagnostic technology. He joins Sequenom from privately held molecular diagnostics firm Primagen, where he served as president of North American operations.
Owings previously served as director of the PCR business unit of Roche Diagnostic Systems, and was vice president of sales and marketing at Digene. Owings also was vice president of sales and marketing at Visible Genetics before that firm was acquired in 2002 by Bayer Diagnostics.

Helicos BioSciences has added Gene Myers to its scientific advisory board. Myers is a professor at the Janelia Farm Research Campus of the Howard Hughes Medical Institute.
He had been vice president of informatics research at Celera Genomics.

Xceed Molecular said this week it has appointed David Deems as president. He replaces Michael Cohen, who will become non-executive chairman of the board. 
Deems was previously vice president of development and operations at Predicant Biosciences, where he had also been vice president of development and operations. He was also vice president of product development at Exact Sciences, CEO of Union Biometrica, and was an executive at BD Biosciences.  

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.